Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1116-1121 , September 2009

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease

  • Joseph Pidala

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • Corresponding Author InformationCorrespondence and reprint requests: Joseph Pidala, MD, Moffitt Cancer Center, 12902 Magnolia Drive, MCC-GME, Tampa, FL 33612-9416.
    • ,
  • Jongphil Kim

      Affiliations

    • Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Teresa Field

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Ali McBride

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Mohamed Kharfan-Dabaja

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Janelle Perkins

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Hugo Fernandez

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Lia Perez

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Ernesto Ayala

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida
    • ,
  • Claudio Anasetti

      Affiliations

    • Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • Department of Oncological Sciences, University of South Florida, Tampa, Florida

Received 25 March 2009 ,Accepted 15 May 2009.

References 

  1. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–394
  2. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–2759
  3. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk factors and outcome. Blood. 1990;75:1024–1030
  4. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964–2968
  5. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med. 2006;354:1813–1826
  6. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–2314
  7. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–2068
  8. Chao NJ, Chen BJ. Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol. 2006;43:32–41
  9. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464–1472
  10. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119–4126
  11. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288–2293
  12. Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-vs.-host disease with antithymocyte globulin. Bone Marrow Transplant. 2001;27:1059–1064
  13. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:40–46
  14. Gluckman E, Devergie A, Varin F, et al. Treatment of steroid-resistant severe acute graft-versus-host disease with a monoclonal pan T OKT3 antibody. Exp Hematol. 1984;12:66
  15. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non–FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99:2712–2719
  16. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:465–471
  17. Herve P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid-resistant acute graft-versus-host disease by in vivo administration of anti–interleukin-2 receptor monoclonal antibody (B-B10). Blood. 1990;75:1017–1023
  18. Wijdenes J, Beliard R, Muot S, et al. A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study. Dev Biol Stand. 1990;71:103–111
  19. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;84:1320–1327
  20. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83–89
  21. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol. 2006;135:382–385
  22. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104:1559–1564
  23. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABXCBL. Blood. 2001;98:2052–2058
  24. Heslop HE, Benaim E, Brenner MK, et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995;346:805–806
  25. MacMillan ML, Couriel D, Weisdorf DJ, et al. A phase II/III multi-center randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007;109:2657–2662
  26. Couriel DR, Hicks K, Giralt S, et al. Role of tumor necrosis factor-alpha inhibition with infliximab in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol. 2000;12:582–587
  27. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005;23:2661–2668
  28. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:1224–1226
  29. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood. 2000;96:2426–2431
  30. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher. 2002;6:296–304
  31. Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005;84:681–685
  32. Stark GL, Richardson AC, Graham JH, et al. Plasma levels of soluble tumor necrosis factor receptor type II correlate with subsequent GVHD development in the sibling allograft setting [abstract]. Blood. 2003;5346a
  33. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-versus-host disease: pathobiology and management. Exp Hematol. 2001;29:259–277
  34. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-versus-host disease. Biol Bone Marrow Transplant. 1999;5:347–356
  35. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  36. Remberger M, Ringden O, Markling L. TNF-alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 1995;15:99–104
  37. Redei I, Knoche J, Tanner AR, et al. Salvage therapy with infliximab for patients with severe acute and chronic GVHD. Blood. 2001;98:399
  38. Magalhaes-Silverman M, Lee CK, Hohl R, et al. Treatment of severe steroid-refractory acute graft-versus-host disease with infliximab. Blood. 2001;98:5208
  39. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid-refractory acute graft-versus host disease with infliximab, a chimeric human/mouse anti-TNF alpha antibody. Bone Marrow Transplant. 2001;28:47–49
  40. Yamane T, Yamamura R, Aoyama Y, et al. Infliximab for the treatment of severe steroid-refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma. 2003;44:2095–2097
  41. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104:649–654
  42. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89:1352–1359
  43. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non- Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768–2776
  44. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825
  45. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956

 Financial disclosure: See Acknowledgments on page 1120.

PII: S1083-8791(09)00253-5

doi: 10.1016/j.bbmt.2009.05.019

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1116-1121 , September 2009

Article Tools

* Image Usage & Resolution